CleanPlex® NGS Panel for Pharmacogenomics Profiling at AMP 2025

–Simple, Accurate, Affordable Solution for Pharmacogenomics Profiling to Identify Genetic Biomarkers Associated with Drug Response–

–Learn More About the Paragon Genomics CleanPlex® NGS Panel at AMP25 Booth # 432—

Fremont, California – November 14, 2025 – Paragon Genomics, Inc., a global leader in target
enrichment solutions for next-generation sequencing (NGS), today announced the launch of its
new CleanPlex® Pharmacogenomics (PGx) NGS Panel at AMP 2025, the annual meeting of the
Association for Molecular Pathology.

Developed in collaboration with pharmacogenomics expert Dr. Ruben Bonilla-Guerrero of Genetica
Consulting Services, the new PGx assay is based on high-level clinical evidence and powered by
Paragon Genomics’ CleanPlex® technology. Leveraging ultra-high amplicon multiplexing capacity
and exceptionally low PCR background noise, the assay delivers a comprehensive, efficient, and
cost-effective PGx solution for research applications.

The NGS-based PGx assay targets 28 key pharmacogenes and features a simple, streamlined
workflow designed to minimize handling errors. It can be performed on all major sequencing
platforms using a variety of sample types, including blood, extracted DNA, buccal swabs, or saliva.
Paragon Genomics also offers a CleanPlex® Custom NGS Panel, enabling researchers to
develop high-performance, targeted assays for oncology, inherited disease, infectious
disease, and agrigenomics applications.

Dr. Bonilla-Guerrero noted, “The new Paragon Genomics CleanPlex® PGx assay is a monumental
step forward in all key elements of PGx testing. From unmatched gene selection and gene coverage
that fulfil regulatory requirements and professional guidelines recommendations, to cost
effectiveness, reliability, and easy-to-use workflow process and robust design, the Paragon
Genomics CleanPlex® PGx assay provides unmatched actionable PGx results and also maximizes
coverage eligibility for payors with dedicated PGx policies. Genetica Consulting Services is proud to
collaborate with Paragon Genomics in the development of the assay and in support of its clients’
bioinformatics and PGx reporting, including complementary professional support for providers,
patients, and organizational leadership.”

Individuals’ response to drug therapy can be significantly affected by the presence or absence of
certain genes or gene variants. Pharmacogenomics aims to ensure that patients receive drugs that
are likely to be safe and effective for them in light of these genetic influences, analyzing relevant
components of the individual’s genetic makeup to predict their drug response and guide drug and
dose selection. The goal is to provide safer, more impactful, and cost-effective treatment.
Traditionally, pharmacogenomics was implemented reactively, but the greater availability and
efficiency of genomic technology is enabling proactive, broad identification of these PGx-related
genetic factors, allowing clinicians and healthcare providers to routinely tailor drug therapy for
optimal effect.

“Introduction of our new PGx sequencing panel is a major milestone for Paragon Genomics,
exemplifying our mission to make the benefits of precision genomics broadly available to improve
human health and well-being,” said Tao Chen, CEO of Paragon Genomics. “The unique advantages of our NGS target enrichment technologies are essential to making PGx profiling widely feasible and accessible. We look forward to working with researchers, laboratories, healthcare
providers and clinicians to achieve wide adoption of this important technology.”

Amplicon-based NGS offers one of the most efficient and scalable approaches for
pharmacogenomic profiling. By targeting genes involved in drug metabolism, efficacy, and toxicity,
researchers can identify variants that affect individual drug response, ultimately improving
therapeutic outcomes.

CleanPlex® PGx Panel and CleanPlex® Custom NGS Panel deliver a
fast, flexible and cost-effective solution for pharmacogenomics research with key advantages
including:
 Ultra-low PCR background, enhancing variant calling accuracy and reducing sequencing
costs
 Rapid workflow completed in just three hours, with only 75 minutes of hands-on time
 Platform-agnostic design, compatible with major sequencing systems by applying different
adapters
 Automation-friendly protocol, easily integrated into automated workflows for high-throughput
applications.

The CleanPlex® panel is designed for flexibility, allowing assay customization based on
population genetics and drug targets of interest. With a focus on precision, simplicity, and
scalability, these tools are helping move pharmacogenomics from concept into routine clinical
and research practice.

About Paragon Genomics
Paragon Genomics is a global leader in amplicon-based target enrichment and NGS library
preparation technologies that accelerate the development of next-generation sequencing assays.
The company’s flagship CleanPlex® technology delivers ultra-sensitive, ultra-multiplexed target
enrichment with exceptional uniformity, low background noise, and compatibility across major
sequencing platforms. CleanPlex enables high-performance sequencing from even challenging
sample types and supports applications across oncology, infectious disease, hereditary genetics,
pharmacogenomics, agrigenomics, and more. Paragon Genomics partners worldwide with
researchers and laboratories to deliver high-quality, customizable NGS solutions. The company is
privately held and headquartered in Fremont, California.

Contacts:
Paragon Genomics Corporate:
Shane Weckhurst Market Development Manager
[email protected]

Paragon Genomics Media:
Barbara Lindheim
BLL Partners for Paragon Genomics
[email protected]
+1 (917) 355-9234